A Brief Guide to Psychedelic Medicine

Psychedelic Medicine: Where it’s At, Where it’s Going

Psychedelic medicine has moved rapidly from the cultural margins into mainstream scientific and medical discourse. Once dismissed as countercultural or unscientific, these compounds are now being studied at leading academic institutions for depression, PTSD, addiction, end-of-life distress, and chronic pain. This newsletter is meant to serve as a foundational refresher on what psychedelic medicine actually is, how these compounds work, and where the science stands today.

What Do We Mean by Psychedelic Medicine?

Psychedelic medicine refers to the therapeutic use of consciousness-altering compounds within a structured clinical framework that typically includes preparation, guided dosing sessions, and integration. While interest in psychedelics may feel new, modern research represents a re-emergence rather than a discovery.

In the 1950s and 1960s, compounds like LSD and psilocybin were actively studied in psychiatry for alcoholism, depression, and existential distress, with more than a thousand papers published before research was abruptly halted. In the early 1970s, these substances were criminalized and classified as Schedule I, effectively freezing clinical research for decades. The modern resurgence began in the 1990s, driven by advances in neuroimaging, improved research ethics, and renewed interest in nontraditional approaches to mental health.

Long before Western psychiatry took interest, Indigenous cultures around the world used psychedelic plants and fungi ceremonially for healing, meaning-making, and community cohesion. Any modern conversation about psychedelic medicine should acknowledge that contemporary research is built on knowledge systems that predate modern science by thousands of years. Clinical models today differ substantially from Indigenous ceremonial use, but honoring these roots is essential to practicing this work with humility and respect.

The Classic Psychedelics

The classic psychedelics include psilocybin, LSD, DMT, and mescaline. Despite their differences, they share a core pharmacologic mechanism. All primarily activate the serotonin 2A receptor, particularly in higher-order cortical regions involved in perception, self-referential thinking, and meaning-making.

Activation of this receptor leads to increased global connectivity, modulation in established brain networks, and enhanced communication between regions that do not typically interact. Neuroimaging studies consistently modulated activity in the default mode network, a system associated with rumination, self-story, and rigid identity patterns. While these compounds share this mechanism, their subjective effects, duration, and clinical applications differ meaningfully.

Psilocybin (“Magic Mushrooms”)

Psilocybin, the active compound in psychedelic mushrooms, has the most robust modern clinical data among the classic psychedelics. It is converted in the body to psilocin, which activates serotonin 2A receptors and promotes transient increases in neural plasticity. Clinical trials have demonstrated significant and durable reductions in depressive symptoms after one or two guided sessions, even in treatment-resistant populations (Carhart-Harris et al., 2016, The Lancet Psychiatry; Davis et al., 2021, JAMA Psychiatry).

Psilocybin is notable for its relatively predictable time course and emotional accessibility. Compared to other psychedelics, experiences are often described as introspective, emotionally rich, and meaning-laden rather than overwhelming. This profile has made psilocybin particularly well suited for therapeutic protocols focused on depression, end-of-life anxiety, and addiction.

LSD (“Acid”)

LSD is a highly potent serotonergic psychedelic with a much longer duration of action, often lasting 8 to 12 hours or more. Like psilocybin, it acts primarily through serotonin 2A receptor activation, though it also interacts with dopaminergic systems, which may contribute to its stimulating and cognitively expansive qualities.

Early research suggested benefit in alcoholism and existential distress, findings that are now being revisited with modern methodologies (Krebs and Johansen, 2012, Journal of Psychopharmacology). LSD experiences are often described as more cognitively complex and perceptually intense than psilocybin, which introduces both therapeutic potential and logistical challenges in clinical settings due to session length.

DMT and Ayahuasca

DMT is a fast-acting serotonergic psychedelic that produces profound alterations in perception and consciousness, often within minutes when administered intravenously or inhaled. Ayahuasca combines DMT with monoamine oxidase inhibitors derived from plants, rendering it orally active and extending the experience.

Neurobiologically, DMT activates serotonin 2A receptors but also appears to engage additional pathways related to emotion and imagery. Observational and neuroimaging studies suggest potential benefit in depression and trauma-related conditions, though much of the data comes from naturalistic and retreat-based contexts rather than randomized controlled trials (Palhano-Fontes et al., 2019, Psychological Medicine).

Experiences are frequently described as immersive and symbolic, sometimes involving encounters with archetypal imagery or a sense of transcendence. These qualities make DMT particularly interesting from a consciousness research perspective, though they also demand careful screening and integration.

Mescaline

Mescaline, derived from plants such as peyote and San Pedro cactus, is one of the oldest known psychedelic compounds used by humans. Like other classic psychedelics, it acts through serotonin 2A receptor activation but has a distinct pharmacologic profile and longer onset.

Modern clinical data are limited, though historical accounts and contemporary observational studies suggest effects on mood, insight, and emotional processing (Rucker et al., 2018, Neuropharmacology). Mescaline experiences are often described as gentler and more embodied, with less perceptual distortion compared to LSD and DMT.

Psychedelic-Like Compounds: Different Pathways, Different Tools

Certain compounds are often grouped with psychedelics due to their therapeutic potential, but they operate through different neurobiological mechanisms and produce distinct subjective effects.

MDMA (“Molly,” “Ecstasy”)

MDMA does not primarily act as a classic psychedelic. Instead, it increases synaptic release of serotonin, dopamine, norepinephrine, and oxytocin while dampening fear responses in the amygdala. This neurochemical profile enhances emotional openness, trust, and memory reconsolidation.

Clinical trials for PTSD have shown striking results, with MDMA-assisted therapy significantly outperforming placebo-assisted psychotherapy (Mitchell et al., 2021, Nature Medicine). Unlike classic psychedelics, MDMA rarely produces perceptual distortions. Its therapeutic value appears to lie in facilitating emotional processing rather than altering sensory perception.

Ketamine

Ketamine operates through NMDA receptor antagonism, leading to downstream glutamate release and rapid synaptogenesis. Unlike serotonergic psychedelics, ketamine produces dissociative rather than psychedelic effects.

Randomized trials have demonstrated rapid antidepressant effects within hours, particularly in treatment-resistant depression and acute suicidality (Zarate et al., 2006, Archives of General Psychiatry). While ketamine can induce meaningful psychological experiences, its therapeutic impact may be more tightly linked to neuroplastic changes than to the subjective experience itself.

A Brief Note on Microdosing

Microdosing refers to the repeated use of sub-perceptual doses of psychedelic compounds. Interest has surged due to claims of improved mood, creativity, and cognitive flexibility. However, placebo-controlled studies suggest that expectancy effects may account for a substantial portion of perceived benefit (Szigeti et al., 2021, eLife).

This tension between subjective experience and objective data is something I explore in depth in a recent episode of my psychedelic podcast, where we discuss what microdosing research is actually showing and what remains unresolved.

Where the Science Is Right Now

Psychedelic science has reached an inflection point. What distinguishes the current era from earlier waves of enthusiasm is not just cultural interest, but the consistency of findings emerging across independent research centers, compounds, and clinical indications. Randomized controlled trials conducted at institutions such as Johns Hopkins, NYU, Imperial College London, and MAPS have repeatedly demonstrated large and clinically meaningful effect sizes, particularly for depression, PTSD, and end-of-life distress (Carhart-Harris et al., 2016, The Lancet Psychiatry; Davis et al., 2021, JAMA Psychiatry; Mitchell et al., 2021, Nature Medicine).

Beyond symptom reduction, studies are converging on shared mechanistic themes. Psychedelic compounds appear to transiently increase neuroplasticity, loosen rigid patterns of brain network activity, and reopen windows for learning and emotional processing in adulthood. Neuroimaging data consistently shows modulated connectivity within the default mode network, alongside increased global brain integration, a pattern associated with reduced rumination and greater cognitive flexibility (Carhart-Harris et al., 2012, PNAS; Daws et al., 2022, Nature Medicine). These effects are not merely acute. Follow-up studies suggest that neural and psychological changes can persist for months after a single guided session.

Equally important, the field has begun to clarify why these therapies work when they do. Outcomes appear to depend less on dose alone and more on the interaction between neurobiology, subjective experience, and structured psychological support. Multiple studies show that the intensity of insight, emotional breakthrough, or meaning-making during the experience predicts long-term benefit, highlighting a therapeutic model that integrates biology and experience rather than separating them (Roseman et al., 2018, Scientific Reports).

Perhaps most promising is the growing precision of the field. Researchers are now moving beyond the question of whether psychedelics work and toward whom they work best for, under what conditions, and how to optimize safety and durability of benefit. Ongoing trials are refining protocols, comparing psychedelics head-to-head with standard treatments, and exploring combination models that integrate psychotherapy, mindfulness, and lifestyle interventions.

Taken together, psychedelic medicine is no longer an exploratory fringe of neuroscience. It represents a coherent and rapidly maturing field that is reshaping how we understand mental health treatment, neuroplasticity, and the role of meaning in healing.

What Is Coming Next

The field continues to evolve rapidly. Ongoing and planned trials include psilocybin for major depressive disorder and alcohol use disorder, MDMA-assisted therapy for PTSD awaiting regulatory review, and expanded investigations into group therapy models, chronic pain, and end-of-life care. Researchers are also exploring how psychedelic-induced neuroplasticity might be combined with psychotherapy, mindfulness training, and lifestyle interventions to improve durability of benefit.

Beyond use in therapeutic settings, we are also starting to dive more into how healing happens, and how these molecules might act differently during different states, particularly when it comes to hormonal health. We know that estrogen modulates serotonin receptor availability, so the thought is that psychedelics likely act differently during different phases of the menstrual cycle or at different times of life. This has long been held by indigenous wisdom, but the science is starting to catch up.

As this research unfolds, psychedelic medicine is increasingly less about any single compound and more about what these tools are teaching us about the mind, meaning, and healing.

This newsletter is meant to serve as a foundation. In future issues, we will go deeper into risks and contraindications, integration practices, ethical considerations, and what psychedelic science may reveal about consciousness itself.

🎧 Explore More on The Trip Lab

A Psychedelic Medicine Podcast

If you’d like to go deeper, I explore many of these topics in more depth on The Trip Lab, a psychedelic medicine podcast I started in 2022. The podcast is a space to slow down and unpack the science, history, and clinical implications of psychedelic medicine beyond headlines and hype.

Episodes dive into how these compounds work in the brain, what current research is actually showing, and how psychedelics intersect with psychotherapy, meaning-making, and consciousness. I also explore questions that do not fit neatly into journal abstracts, including why subjective experience matters, how set and setting shape outcomes, and what this research may be teaching us about the mind itself.

Here are several notable episodes if you’d like to explore further.

#3 – An Rx for Magic Mushrooms & LSD

#4 – MDMA for PTSD

#12 – Unlock Your Mind: Psychedelics in Physics, Creativity & Religion

#18 – Psychedelics an the Feminine: Healing Cycles, Hormones, and the Womb

#21 – Psychedelics & Mystical Experiences: Why Medicine is Uncomfortable Talking About Them

#24 – Microdosing Psychedelics: Evidence Updates, the Placebo Response, and the Neuroscience Behind Why It May (or May Not) Work